vTv Therapeutics Inc. (VTVT)
| Market Cap | 301.92M +75.5% |
| Revenue (ttm) | 36.84M +216,600.0% |
| Net Income | -4.76M |
| EPS | -0.42 |
| Shares Out | 12.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,690 |
| Open | 23.55 |
| Previous Close | 23.55 |
| Day's Range | 23.55 - 24.35 |
| 52-Week Range | 22.45 - 44.00 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 56.00 (+130.45%) |
| Est. Earnings | Nov 17, 2026 |
About VTVT
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for VTVT stock is "Strong Buy." The 12-month stock price target is $56.0, which is an increase of 130.45% from the latest price.
News
vTv Therapeutics randomizes first participant in CATT1 pilot study
vTv Therapeutics (VTVT) announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop, o...
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insu...
vTv Therapeutics Transcript: KOL event
Hypoglycemia remains common and burdensome despite CGM and AID, with survey data indicating clinically meaningful burdens across T1D populations. CATT1 is testing whether cadisegliatin can reduce hypoglycemia by 30% without sacrificing HbA1c; top-line results are expected mid-2027.
vTv Therapeutics Slides: KOL event
vTv Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
vTv Therapeutics to hold a conference call
Management holds a conference call to discuss Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20 at 2:30 pm. Webcast Link
vTv Therapeutics announces presentation at T1D clinical, research progress
vTv Therapeutics (VTVT) announced that Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin deli...
vTv Therapeutics Slides: Study presentation
vTv Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 11, 2026.
vTv Therapeutics granted Orphan Drug Designation for HPPD
vTv Therapeutics (VTVT) announced that the FDA has granted Orphan Drug Designation to HPPD, the company’s oral Nrf2/Bach1 modulator. HPPD is being investigated as a treatment for sickle cell disease.
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions for...
vTv Therapeutics completes enrollment in CATT1 study
vTv Therapeutics (VTVT) announced on October 5 that the company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes study. A total of 166…
vTv Therapeutics treatment of sickle cell granted orphan designation
vTv Therapeutics (VTVT) was granted FDA orphan designation for treatment of sickle cell disease, according to a post to the agency’s website.
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type ...
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027
vTv Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Cadisegliatin, a liver-selective glucokinase activator, is advancing through phase III trials for type 1 diabetes, aiming to reduce hypoglycemia and improve glycemic control. Enrollment for the pivotal CATT1 trial is on track, with top-line data expected in 2027 and sufficient funding secured.
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-...
vTv Therapeutics to Participate in September Investor Conferences
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type...
vTv Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of vTv Therapeutics (VTVT) with an Outperform rating and $60 price target
vTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on vTv Therapeutics (VTVT) to $42 from $45 and keeps a Buy rating on the shares post the Q2 report. The firm cites…
vTv Therapeutics reports Q2 EPS ($1.05), consensus (99c)
“Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D,” said Paul Sekhri, Chair...
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid...
vTv Therapeutics Quarterly report: Q2 2026
vTv Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
vTv Therapeutics Earnings release: Q2 2026
vTv Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
vTv Therapeutics price target raised to $57 from $49 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on vTv Therapeutics (VTVT) to $57 from $49 and keeps a Buy rating on the shares. The firm highlights cadisegliatin as…
vTv Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $67 price target
vTv Therapeutics Transcript: AGM 2026
The meeting established a quorum and proceeded with votes on director elections, auditor ratification, and executive compensation. All director nominees were elected, Ernst & Young was ratified as auditor, but the advisory vote on executive compensation did not pass.